Recombinant TNFSF11 (Denosumab Biosimilar) anticorps

N° du produit ABIN7200656

Cet anticorps Souris Monoclonal détecte spécifiquement TNFSF11 (Denosumab Biosimilar) dans FACS et in vivo. Il présente une réactivité envers Humain.

Aperçu rapide pour Recombinant TNFSF11 (Denosumab Biosimilar) anticorps (ABIN7200656)

Antigène: TNFSF11 (Denosumab Biosimilar)

Type d'anticorp: Recombinant Antibody

Reactivité: Humain

Hôte: Souris

Clonalité: Monoclonal

Conjugué: Cet anticorp TNFSF11 (Denosumab Biosimilar) est non-conjugé

Application: Flow Cytometry (FACS), In vivo Studies (in vivo)

Détail du produit anti-TNFSF11 (Denosumab Biosimilar) anticorps

Fonction: Denosumab Biosimilar, Human RANKL Monoclonal Antibody

Specificité: The monoclonal antibody denosumab biosimilar specifically binds to the human RANKL (RANK ligand) protein.

Attributs du produit: Recombinant Humanized IgG2 Monoclonal Antibody.

Purification: Protein A affinity column

Pureté: > 95% by SDS-PAGE under reducing conditions and HPLC.

Stérilité: 0.2 μm filtered

niveau d'endotoxine: < 1 EU per 1 mg of the protein by the LAL method.

Immunogène: The monoclonal antibody denosumab biosimilar was produced in the denosumab biosimilar CHO stable cell line.

Isotype: IgG2 kappa

Information d'application

Indications d'application: ELISA, neutralization, functional assays such as bioanalytical PK and ADA assays, and those assays for studying biological pathways affected by denosumab.

Restrictions: For Research Use only

Stockage

Format: Liquid

Concentration: 1 mg/mL

Buffer: PBS, pH 7.4, no stabilizers or preservatives.

Agent conservateur: Without preservative

Conseil sur la manipulation: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.

Stock: -20 °C

Stockage commentaire: 12 months from date of receipt, -20 to -70°C as supplied. 1 month from date of receipt, 2 to 8°C as supplied.

Date de péremption: 12 months

Détails sur TNFSF11 (Denosumab Biosimilar)

Antigène: TNFSF11 (Denosumab Biosimilar)

Classe de substances: Biosimilar

Sujet: Denosumab, a fully human monoclonal antibody, inhibits the RANKL (RANK ligand) protein, the primary signal for bone removal. Denosumab can be used for the treatment of osteoporosis, treatment-induced bone loss, bone metastases, multiple myeloma, and giant cell tumor of bone.